NCT04896853View on ClinicalTrials.gov

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

March 31, 2027

Study Completion Date

May 31, 2027

Conditions
COVID-19 Acute Respiratory Distress SyndromeInfluenza AMetapneumovirus PneumoniaRespiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

ProTrans®

Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells

Trial Locations (1)

701 85

Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro

Sponsors

Lead Sponsor

NextCell Pharma Ab
All Listed Sponsors
collaborator

Karolinska Trial Alliance

INDUSTRY

lead

NextCell Pharma Ab

INDUSTRY

NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® | Biotech Hunter | Biotech Hunter